These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 19671047)
1. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Semenza GL Curr Pharm Des; 2009; 15(33):3839-43. PubMed ID: 19671047 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of HIF-1 inhibitors as anticancer agents. Semenza GL Drug Discov Today; 2007 Oct; 12(19-20):853-9. PubMed ID: 17933687 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Xia Y; Choi HK; Lee K Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612 [TBL] [Abstract][Full Text] [Related]
4. Cancer therapeutic agents targeting hypoxia-inducible factor-1. Wang R; Zhou S; Li S Curr Med Chem; 2011; 18(21):3168-89. PubMed ID: 21671859 [TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-1 in human breast and prostate cancer. Kimbro KS; Simons JW Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428 [TBL] [Abstract][Full Text] [Related]
6. Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Yoo YD; Lee JC Oncol Rep; 2009 Mar; 21(3):801-7. PubMed ID: 19212642 [TBL] [Abstract][Full Text] [Related]
7. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity. Wang KS; Ma J; Mi C; Li J; Lee JJ; Jin X Oncol Rep; 2016 Apr; 35(4):2045-52. PubMed ID: 26781327 [TBL] [Abstract][Full Text] [Related]
8. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Patiar S; Harris AL Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560 [TBL] [Abstract][Full Text] [Related]
9. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α. Ao Q; Su W; Guo S; Cai L; Huang L Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925 [TBL] [Abstract][Full Text] [Related]
10. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Rohwer N; Cramer T Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972 [TBL] [Abstract][Full Text] [Related]
11. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. Tafani M; De Santis E; Coppola L; Perrone GA; Carnevale I; Russo A; Pucci B; Carpi A; Bizzarri M; Russo MA Biomed Pharmacother; 2014 Feb; 68(1):1-5. PubMed ID: 24286852 [TBL] [Abstract][Full Text] [Related]
12. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Brown LM; Cowen RL; Debray C; Eustace A; Erler JT; Sheppard FC; Parker CA; Stratford IJ; Williams KJ Mol Pharmacol; 2006 Feb; 69(2):411-8. PubMed ID: 16254058 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer. Nakamura J; Kitajima Y; Kai K; Mitsuno M; Ide T; Hashiguchi K; Hiraki M; Miyazaki K Oncol Rep; 2009 Oct; 22(4):693-9. PubMed ID: 19724845 [TBL] [Abstract][Full Text] [Related]
14. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872 [TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267 [TBL] [Abstract][Full Text] [Related]
16. Involvement of hypoxia-inducible factor 1 in human cancer. Semenza GL Intern Med; 2002 Feb; 41(2):79-83. PubMed ID: 11868612 [TBL] [Abstract][Full Text] [Related]
17. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Lee K; Kang JE; Park SK; Jin Y; Chung KS; Kim HM; Lee K; Kang MR; Lee MK; Song KB; Yang EG; Lee JJ; Won M Biochem Pharmacol; 2010 Oct; 80(7):982-9. PubMed ID: 20599784 [TBL] [Abstract][Full Text] [Related]
18. Recent agents targeting HIF-1α for cancer therapy. Hu Y; Liu J; Huang H J Cell Biochem; 2013 Mar; 114(3):498-509. PubMed ID: 22961911 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342 [TBL] [Abstract][Full Text] [Related]
20. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]